Lloyd’s, der weltweit führende Versicherungsmarkt, hat dem MCI Syndicate 1966 die Genehmigung erteilt, eine Versicherung für klinische Studien anzubieten, die durch die MAT KI-Plattform von GATC ermöglicht wird, um das finanzielle Risiko bei der Entwicklung von therapeutischen…

Lloyd’s, der weltweit führende Versicherungsmarkt, hat dem MCI Syndicate 1966 die Genehmigung erteilt, eine Versicherung für klinische Studien anzubieten, die durch die MAT KI-Plattform von GATC ermöglicht wird, um das finanzielle Risiko bei der Entwicklung von therapeutischen…

Lloyd’s, the world’s leading insurance market, has granted approval to MCI Syndicate 1966 to offer insurance for clinical trials, facilitated by GATC’s MAT AI platform, to greatly reduce the financial risk in therapeutic drug development. IRVINE, Calif. and LONDON, July 22, 2024…

Lloyd’s, the world’s leading insurance market, has granted approval to MCI Syndicate 1966 to offer insurance for clinical trials, facilitated by GATC’s MAT AI platform, to greatly reduce the financial risk in therapeutic drug development. IRVINE, Calif. and LONDON, July 22, 2024…

Lloyd’s, the world’s leading insurance market, has granted approval to MCI Syndicate 1966 to offer insurance for clinical trials, facilitated by GATC’s MAT AI platform, to greatly reduce the financial risk in therapeutic drug development. IRVINE, Calif. and LONDON, July 22, 2024…

Lloyd’s, the world’s leading insurance market, has granted approval to MCI Syndicate 1966 to offer insurance for clinical trials, facilitated by GATC’s MAT AI platform, to greatly reduce the financial risk in therapeutic drug development. IRVINE, Calif. and LONDON, July 22, 2024…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.